Bivatuzumab mertansine

Bivatuzumab mertansine
Monoclonal antibody

Type	Whole antibody
Source	Humanized (from mouse)
Target	CD44 v6
Clinical data
ATC code	none
Identifiers
ChemSpider	none
^NY (what is this?) (verify)

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.^[1]

References

↑ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Tarextumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Abituzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Vandortuzumab vedotin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin Ontuxizumab

Veterinary ("-tuvet-")	Blontuvetmab Tamtuvetmab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 6/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.